GI
ARQT icon

GAMMA Investing’s Arcutis Biotherapeutics ARQT Stock Holding History

GAMMA Investing’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.3K Buy
1,337
+323
+32% +$8.45K ﹤0.01% 2594
2026
Q2 		$26.6K Sell
1,014
-81
-7% -$1.89K ﹤0.01% 2686
2026
Q1 		$25.8K Buy
1,095
+56
+5% +$1.43K ﹤0.01% 2583
2025
Q4 		$30.2K Buy
1,039
+325
+46% +$8.32K ﹤0.01% 2390
2025
Q3 		$13.5K Buy
714
+22
+3% +$347 ﹤0.01% 2719
2025
Q2 		$9.7K Sell
692
-300
-30% -$4.21K ﹤0.01% 2819
2025
Q1 		$15.5K Sell
992
-148
-13% -$2.08K ﹤0.01% 2528
2024
Q4 		$15.9K Buy
1,140
+83
+8% +$909 ﹤0.01% 2384
2024
Q3 		$9.83K Buy
1,057
+5
+0.5% +$49 ﹤0.01% 2468
2024
Q2 		$9.78K Buy
1,052
+4
+0.4% +$36 ﹤0.01% 2266
2024
Q1 		$10.4K Buy
1,048
+582
+125% +$4.34K ﹤0.01% 2050
2023
Q4 		$2.73K Buy
+466
New +$1.27K ﹤0.01% 2478

Other funds holding ARQT

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's ARQT Position: Q3 2026 in Review

GAMMA Investing increased its Arcutis Biotherapeutics (ARQT) stake by 32% in Q3 2026, buying an estimated $8.45K and bringing the position to 1,337 shares worth $35.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2594.

GAMMA Investing first reported a position in ARQT in Q4 2023 and has held it in 12 quarters since. 7 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • GAMMA Investing held 1,337 shares of Arcutis Biotherapeutics worth $35.3K as of Q3 2026.
  • GAMMA Investing bought 323 Arcutis Biotherapeutics shares in Q3 2026, an estimated $8.45K.
  • Arcutis Biotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2594 holding.
  • GAMMA Investing first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 12 quarters since.
  • 7 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.